Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03639337
Other study ID # 787_OPBG_2014
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2015
Est. completion date August 2018

Study information

Verified date August 2018
Source Bambino Gesù Hospital and Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the addition of three probiotics (Bifidobacterium longum, Bifidobacterium breve and Bifidobacterium infantis) in the treatment of pediatric food allergic children to milk or egg. The allergic participants will receive the probiotics, while other two populations age and sex matched of not confirmed allergic and healthy children will not receive probiotics.


Description:

This study evaluates the colonization capacity of three probiotics (Bifidobacterium longum, Bifidobacterium breve and Bifidobacterium infantis) in milk and/or egg allergic children.

It is expected the recruitment of about 20 egg and/or milk allergic patients aged between 10 and 14 months old confirmed with double-blind oral tolerance test against placebo (Group 1).

Furthermore, about 10 patients sensible to milk or egg but not confirmed with double-blind oral tolerance test against placebo (Group 2) will be recruited and about 10 healthy individuals (Group 3).

For all 40 patients:

1. Baseline presence of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63 will be evaluated;

Only for Group 1 children it will be also evaluate:

2. The presence of the same strains during 30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63 and after 60 days from the suspension of the administration.

Quantification of B. breve, B. longum subsp. longum and B. longum subsp. infantis in faecal samples was carried out by qRT-PCR using the Light Cycler 480 platform (Roche Diagnostics, Mannheim, Germany). The assays were performed with a 20 µl PCR amplification mixture containing: 10 µl LightCycler 480 Probe Master mix (Roche Diagnostics), 2 µl primers and probes (optimized concentrations, 0.5 µM and 0.1 µM, respectively), 3 µl molecular-grade H2O and 5 µl DNA template. Each sample was tested in duplicate to ensure data reproducibility. The RT-PCR temperature profile consisted of an initial denaturation at 95°C for 10 min, 45 amplification cycles at 95°C for 10 sec, 60°C for 30 sec and 72°C for 1 sec followed by a final cooling step at 40°C for 30 sec. Absolute quantification was performed using the "second derivative maximum method"

Statistical analyses: Wilcoxon signed-rank test was used to compare probiotic species concentrations during the time-course.


Recruitment information / eligibility

Status Completed
Enrollment 33
Est. completion date August 2018
Est. primary completion date August 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 10 Months to 14 Months
Eligibility Inclusion Criteria:

- Age between 10 and 14 months

Exclusion Criteria:

- gastrointestinal disease in progress or appearance in the last 30 days

- metabolic diseases

- antibiotic treatment in the 2 weeks prior to the start of the study;

- intake of probiotic, fermented milk or other functional foods in the two weeks preceding the start of the study.

Study Design


Intervention

Dietary Supplement:
Multi-strain probiotic
30 days of administration of multi-strain probiotics containing 3.5 x 109 UFC of Bifidobacterium longum BB536, Bifidobacterium breve M-16V and Bifidobacterium infantis M-63

Locations

Country Name City State
Italy Ospedale Pediatrico Bambino Gesù Roma

Sponsors (1)

Lead Sponsor Collaborator
Bambino Gesù Hospital and Research Institute

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Basal stool concentration of Bifidobacterium longum BB536, Bifidobacterium breve M-16V It will be indicated number of cells per ul of stool. 2 years
Secondary Stool concentration of Bifidobacterium longum BB536, Bifidobacterium breve M-16V after multi-strain probiotic administration. It will be indicated number of cells per ul of stool. 2 years
See also
  Status Clinical Trial Phase
Completed NCT01904604 - Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Phase 2
Enrolling by invitation NCT04885959 - The Effects of Traditional Asian Diet on Gut Microbiome and Metabolome in Healthy Volunteers and Pregnancy on Subsequent Infant's Allergy Development N/A
Recruiting NCT03974555 - Epidemiological Investigation and Cohort Study on Food Allergy in Children Aged 3 to 6 Years in Wenzhou and Taizhou Urban Areas
Recruiting NCT05177744 - Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
Completed NCT01420705 - Bacille Calmette-Guérin (BCG) Vaccine and Atopy N/A
Completed NCT00850668 - Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults Phase 1
Withdrawn NCT00736112 - Food Allergy - Tubes - Adenoids (FATA) Trial N/A
Active, not recruiting NCT00298337 - Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 Phase 2/Phase 3
Completed NCT03693456 - Food Allergy Diagnostic Test Response to Previous Oral Challenge Response N/A
Completed NCT00461097 - Oral Immunotherapy for Childhood Egg Allergy Phase 2
Completed NCT02606721 - Food Allergy Challenge Diagnostic Study
Active, not recruiting NCT02457416 - Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut N/A
Completed NCT02825069 - Study on the Induction of Food Tolerance in Babies N/A
Completed NCT02350660 - Oral Immunotherapy for Peanut and Mammalian Meat Allergies N/A
Completed NCT01084174 - A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy Phase 1/Phase 2
Completed NCT00597675 - Oral Immunotherapy for Peanut Allergy (PMIT) Phase 2
Completed NCT00932828 - Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study Phase 2
Completed NCT01373242 - Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Phase 1/Phase 2
Completed NCT00578656 - An Interventional Study of Milk Allergy Phase 0
Completed NCT00356174 - An Observational Study of Childhood Food Allergy N/A